CSR and Sustainability in the News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 8, Issue 8

Merck & Co. and the Bill & Melinda Gates Foundation have formed a partnership to expand access to family planning, particularly in the developing world. Merck is pledging $25 million over eight years as part of its Merck for Mothers program, a 10-year initiative to reduce maternal mortality.

In other news, Merck & Co. has launched a three-year, $3-million initiative to support health departments in Atlanta, Houston, and Philadelphia, to enhance existing efforts and foster other innovative approaches to better serve people living with HIV/AIDS and prevent is further spread. The program supports the HIV Care Collaborative for Underserved Populations in the United States.

Merck & Co. also announced the first five partnership and inaugural class of fellows for newly formed Richard T. Clark Fellowship program, with PSI, a global nonprofit organized working to improve the health of people in the developing world. The program aims to strengthen the capability and reach of charitable organizations focused on improving access to health services and health outcomes.

Roche supported the “Roche Continents” program at the Salzburg Festival. The program invited 100 students from Europe to discover the role of innovation in the arts and science during a progam of workshops, discussions, and concert series.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here